WST Stock Analysis — West Pharmaceutical Services
Sector: Healthcare
AI Verdict
At 34x next year's earnings and 28% expected EPS growth, you're paying up for a specialized packaging moat, but the current price bakes in flawless execution and leaves little room for disappointment.
Competitive Moat
West Pharmaceutical Services dominates the market for injectable drug packaging and delivery systems, supplying proprietary stoppers, seals, and syringes that are critical for pharma clients' regulatory compliance. Its moat comes from deep integration with major drugmakers’ manufacturing processes, making switching costly and risky for customers.
Summary
WST's 52.97% one-year return and 79.1 RSI signal a stock riding high on expectations for its specialized pharma packaging business.
Where It Stands
With a 1-year return of 52.97%, a 79.1 RSI (deeply overbought), and a forward P/E of 34.0x versus the healthcare sector's 22x median, WST is trading at a premium on strong momentum.
Key Metrics
- RSI: 79.1 — Overbought
- Trailing P/E: 43.6x
- Forward P/E: 34.0x
- PEG Ratio: 1.54
- Earnings Growth: +0.3%
- Revenue Growth: +0.1%
- Market Cap: $23.0B
- Dividend Yield: 0.00%
- 1-Year Return: 52.97%
- 52-Week High: $328.44
- 52-Week Low: $202.79
Analyst Consensus
19 Buy · 4 Hold · 0 Sell (23 analysts)
Bull Case
Forward EPS is expected to grow 28.3% while the stock trades at 34.0x next year's earnings, which is a fair multiple if it delivers on that growth.
Bear Case
If the P/E reverts to the sector median of 22x, the stock could see a 35%+ drop from current valuation levels, especially with an RSI of 79.1 indicating overbought conditions.
Catalyst to Watch
Watch for major pharma contract wins or regulatory changes that could either reinforce or undermine its integration moat.